Pharmaceutical Product Monograph: Amikacin Sulfate Injection (250 mg, 500 mg)
In the pharmaceutical industry, Amikacin Sulfate is a semi-synthetic Aminoglycoside antibiotic derived from Kanamycin. As a pharmacist and manufacturer, I view this molecule as a “Reserve Antibiotic”—it is technically designed to remain effective against multi-drug-resistant (MDR) Gram-negative bacteria that have developed resistance to other aminoglycosides like Gentamicin or Tobramycin.
At your WHO-GMP facility in Mumbai, Amikacin is a critical SKU for Tertiary Care and ICU settings. Because of its potency and potential for toxicity, its use is strictly reserved for severe, life-threatening infections.
Therapeutic Profile: Clinical Indications
Amikacin is indicated for the short-term treatment of serious infections caused by susceptible strains of Gram-negative bacteria.
| Indication | Clinical Context | Technical Rationale |
| Septicemia | Bacterial Sepsis | Used as empirical therapy in life-threatening blood infections, often combined with a Beta-lactam. |
| Nosocomial Pneumonia | Hospital-Acquired | Targets Pseudomonas aeruginosa and Acinetobacter in ventilator-associated cases. |
| Intra-abdominal Infections | Post-Surgical | Treats peritonitis and complex infections following abdominal trauma or surgery. |
| Complex UTIs | Urinary Tract | Reserved for severe, recurrent kidney infections (pyelonephritis) resistant to first-line drugs. |
| MDR-TB | Tuberculosis | Part of the specialized “second-line” regimen for Multi-Drug Resistant Tuberculosis. |
Mechanism: Irreversible Protein Synthesis Inhibition
Amikacin exerts a bactericidal effect by disrupting the “blueprints” of the bacterial cell:
Ribosomal Binding: It binds irreversibly to the 30S subunit of the bacterial ribosome.
Genetic Misreading: It causes a “misreading” of the genetic code (mRNA), leading to the production of non-functional or toxic proteins.
Membrane Disruption: These “bad proteins” insert themselves into the bacterial cell membrane, causing it to leak and eventually leading to cell death.
Post-Antibiotic Effect (PAE): Technically, Amikacin continues to kill bacteria even after blood levels have dropped, which allows for once-daily dosing in some patients.
The Pharmacist’s “Technical Warning”
The “Oto-Renal” Risk: As a pharmacist, I must emphasize that Amikacin is Nephrotoxic (kidney damaging) and Ototoxic (hearing/balance damaging). Hearing loss can be permanent and may occur even after the drug is stopped.
Trough & Peak Monitoring: For B2B hospital clients, emphasize the need for Therapeutic Drug Monitoring (TDM). Blood levels must be checked to ensure they stay within the “safety window” to prevent kidney failure.
Neuromuscular Blockade: Amikacin can worsen muscle weakness in patients with Myasthenia Gravis or those receiving muscle relaxants during surgery.
Hydration Status: Patients must be exceptionally well-hydrated to help the kidneys flush the drug out of the system.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Sterile Fill” USP: On your digital marketplace, highlight your Aseptic Filling Line. Amikacin is heat-sensitive; ensuring a 100% sterile, pyrogen-free vial is a major technical benchmark for WHO-GMP compliance.
Sulfite Sensitivity: Most formulations contain Sodium Bisulfite. For premium export markets, offering “Sulfite-Free” or “Preservative-Free” vials is a significant technical advantage for B2B ICU tenders.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Amikacin 500 mg/2 mL injections to support your registration in international tenders for emergency medicine and respiratory care.